Bridgeway Capital Management LLC Sells 24,500 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Bridgeway Capital Management LLC reduced its stake in Prestige Consumer Healthcare Inc. by 26.3%, holding 68,500 shares worth approximately $5.89 million after selling 24,500 shares in the first quarter.
• Prestige Consumer Healthcare reported a net loss in earnings, with EPS of $0.95 for the last quarter, missing estimates by $0.06 and reflecting a 6.6% decline in revenue compared to the same period last year.
• The stock is currently rated as a "Moderate Buy" by analysts, with a consensus target price of $93.33, and a market capitalization of $3.28 billion.

Bridgeway Capital Management LLC lowered its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 26.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,500 shares of the company's stock after selling 24,500 shares during the quarter. Bridgeway Capital Management LLC owned about 0.14% of Prestige Consumer Healthcare worth $5,889,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter valued at $84,932,000. Invesco Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after purchasing an additional 261,537 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock worth $15,923,000 after acquiring an additional 186,524 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Prestige Consumer Healthcare by 11,580.3% in the 1st quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock worth $13,887,000 after acquiring an additional 160,155 shares during the last quarter. Finally, Neumeier Poma Investment Counsel LLC bought a new stake in Prestige Consumer Healthcare in the 1st quarter worth about $8,713,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 2.0%

NYSE:PBH traded down $1.33 during trading hours on Wednesday, reaching $64.68. The company's stock had a trading volume of 94,858 shares, compared to its average volume of 404,828. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of 15.19, a PEG ratio of 2.08 and a beta of 0.46. The firm has a 50-day simple moving average of $71.47 and a 200-day simple moving average of $79.63. Prestige Consumer Healthcare Inc. has a 1 year low of $62.95 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare's revenue was down 6.6% on a year-over-year basis. During the same period last year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PBH. Zacks Research downgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.